Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD II
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
A. Pacheco, M. Hinojosa, J. Gonzalez, B. Huertas, D. Antolin, C. Vidal (Madrid, Spain). Improvement of control and quality of life in severe allergic asthmatics patients treated with omalizumab. Eur Respir J 2008; 32: Suppl. 52, 3669

Member's Comments

No comment yet.

Related content which might interest you: Improvements in asthma control and quality of life with omalizumab in allergic (IgE-mediated) asthma patients Source: Annual Congress 2012 - Trials in asthma: asthma exacerbations and severe asthma Year: 2012 Effectiveness of omalizumab in improving quality of life in patients with ‘steroid-resistant‘ asthma and severe allergic rhinitis Source: Annual Congress 2012 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2012 Omalizumab improves asthma-specific quality of life in patients with severe allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001 Omalizumab significantly improves quality of life in patients with severe persistent allergic asthma: a pooled analysis Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Predictors of response to therapy with omalizumab in patients with severe allergic asthma–a real life study Source: International Congress 2017 – Monitoring asthma control Year: 2017 The effect of allergic rhinitis on quality of life and sleep quality in asthmatic patients Source: Eur Respir J 2006; 28: Suppl. 50, 443s Year: 2006 Effect of omalizumab treatment on allergic comorbidities in patients with severe allergic asthma – real life experience from Czech Anti-IgE Registry Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control Source: Annual Congress 2012 - Clinical diagnosis and treatment of adult asthma Year: 2012 The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Source: Eur Respir J 2002; 20: 1088-1094 Year: 2002 Quality of life in patients with asthma or rhinitis Source: Eur Respir J 2002; 20: Suppl. 38, 120s Year: 2002 10 Year evaluation of patients with severe uncontrolled allergic asthma treated with Omalizumab. Source: International Congress 2018 – Physiological and biological insights in asthma Year: 2018 Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey Source: Eur Respir J 2013; 42: 1224-1233 Year: 2013 Impact of omalizumab in patients with severe asthma Source: Annual Congress 2009 - Aspects of uncontrolled asthma Year: 2009 Follow-up of patients with moderate-severe allergic asthma treated with omalizumab Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Assesment of long-term omalizumab treatment in severe allergic asthma Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE Year: 2012 Quality of life in children with asthma associated with allergic rhinitis Source: Annual Congress 2009 - How viruses, allergic rhinitis and air pollution affect childhood asthma Year: 2009 Dupilumab improves asthma control and quality of life in children with uncontrolled persistent asthma Source: Virtual Congress 2021 – Paediatric allergic asthma: novel therapeutics and monitoring approaches Year: 2021 Quality of life, clinical symptoms and nasal obstruction in patients with allergic rhinitis Source: Eur Respir J 2003; 22: Suppl. 45, 418s Year: 2003 Paediatric asthma quality of life evaluation after Becotide® treatment of asthmatic children Source: Eur Respir J 2001; 18: Suppl. 33, 145s Year: 2001